The CLL cohort tracks 8 patients that previously received 1 to 8 lines of standard treatment, and then were treated with venetoclax (BCL2-inhibitor) but developed resistance with median time of 15 months to relapse. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.